Additionally, the 36-month beta value for CLDX is 1.40. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for CLDX is 64.70M and currently, short sellers hold a 13.57% ratio of that float. The average trading volume of CLDX on April 29, 2025 was 799.76K shares.
CLDX) stock’s latest price update
Celldex Therapeutics Inc (NASDAQ: CLDX) has experienced a rise in its stock price by 9.15 compared to its previous closing price of 19.57. However, the company has seen a gain of 12.78% in its stock price over the last five trading days. globenewswire.com reported 2025-03-04 that HAMPTON, N.J., March 04, 2025 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:
CLDX’s Market Performance
Celldex Therapeutics Inc (CLDX) has seen a 12.78% rise in stock performance for the week, with a 6.91% gain in the past month and a -12.96% plunge in the past quarter. The volatility ratio for the week is 4.31%, and the volatility levels for the past 30 days are at 7.30% for CLDX. The simple moving average for the past 20 days is 20.04% for CLDX’s stock, with a -23.69% simple moving average for the past 200 days.
Analysts’ Opinion of CLDX
Morgan Stanley, on the other hand, stated in their research note that they expect to see CLDX reach a price target of $46. The rating they have provided for CLDX stocks is “Overweight” according to the report published on March 20th, 2025.
UBS gave a rating of “Buy” to CLDX, setting the target price at $44 in the report published on February 13th of the current year.
CLDX Trading at 9.29% from the 50-Day Moving Average
After a stumble in the market that brought CLDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.55% of loss for the given period.
Volatility was left at 7.30%, however, over the last 30 days, the volatility rate increased by 4.31%, as shares surge +7.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.37% lower at present.
During the last 5 trading sessions, CLDX rose by +12.78%, which changed the moving average for the period of 200-days by -41.69% in comparison to the 20-day moving average, which settled at $17.79. In addition, Celldex Therapeutics Inc saw -15.47% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLDX starting from Marucci Anthony S, who purchase 11,500 shares at the price of $26.82 back on Nov 11 ’24. After this action, Marucci Anthony S now owns 40,284 shares of Celldex Therapeutics Inc, valued at $308,430 using the latest closing price.
Martin Samuel Bates, the SVP AND CFO of Celldex Therapeutics Inc, sale 17,172 shares at $35.42 during a trade that took place back on Jun 14 ’24, which means that Martin Samuel Bates is holding 28,125 shares at $608,315 based on the most recent closing price.
Stock Fundamentals for CLDX
Current profitability levels for the company are sitting at:
- -27.79 for the present operating margin
- 0.78 for the gross margin
The net margin for Celldex Therapeutics Inc stands at -22.49. The total capital return value is set at -0.26. Equity return is now at value -26.84, with -25.10 for asset returns.
Based on Celldex Therapeutics Inc (CLDX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -41.38.
Currently, EBITDA for the company is -191.9 million with net debt to EBITDA at 0.13. When we switch over and look at the enterprise to sales, we see a ratio of 198.49. The receivables turnover for the company is 10.03for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.91.
Conclusion
In conclusion, Celldex Therapeutics Inc (CLDX) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
